Zain Ebrahim
Stock Analyst at J.P. Morgan
(1.14)
# 3,679
Out of 4,504 analysts
31
Total ratings
50%
Success rate
-2.8%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Maintained: Sell | 1,700p | $1,961.50 | -13.33% | 21 | Jun 29, 2026 | |
| EPA: EAPI Euroapi S.A. | Maintained: Hold | €1.70 | $1.26 | +35.35% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Maintained: Buy | 2,400p → 2,000p | $1,584.00 | +26.26% | 2 | Mar 3, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Hold | kr 1,650 → kr 2,050 | $1,888.98 | +8.52% | 2 | Dec 8, 2025 | |
| LON: OXB Oxford Biomedica plc | Maintained: Hold | 550p | $611.00 | -9.98% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 675.00 | $586.00 | +15.19% | 1 | Jul 28, 2025 | |
| SWX: BANB Bachem Holding AG | Maintained: Buy | CHF 74.00 → CHF 85.00 | $74.85 | +13.56% | 3 | Jul 25, 2025 |
GSK plc
Jun 29, 2026
Maintained: Sell
Price Target: 1,700p
Current: $1,961.50
Upside: -13.33%
Euroapi S.A.
May 13, 2026
Maintained: Hold
Price Target: €1.70
Current: $1.26
Upside: +35.35%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Maintained: Buy
Price Target: 2,400p → 2,000p
Current: $1,584.00
Upside: +26.26%
Genmab A/S
Dec 8, 2025
Maintained: Hold
Price Target: kr 1,650 → kr 2,050
Current: $1,888.98
Upside: +8.52%
Oxford Biomedica plc
Dec 8, 2025
Maintained: Hold
Price Target: 550p
Current: $611.00
Upside: -9.98%
Lonza Group AG
Jul 28, 2025
Maintained: Buy
Price Target: CHF 675.00
Current: $586.00
Upside: +15.19%
Bachem Holding AG
Jul 25, 2025
Maintained: Buy
Price Target: CHF 74.00 → CHF 85.00
Current: $74.85
Upside: +13.56%